Vivera Pharmaceuticals Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Vivera Pharmaceuticals's estimated annual revenue is currently $4.4M per year.(i)
  • Vivera Pharmaceuticals's estimated revenue per employee is $201,000

Employee Data

  • Vivera Pharmaceuticals has 22 Employees.(i)
  • Vivera Pharmaceuticals grew their employee count by -12% last year.

Vivera Pharmaceuticals's People

NameTitleEmail/Phone
1
Co-Founder and VP SalesReveal Email/Phone
2
Chief Commercial OfficerReveal Email/Phone
3
Human Resources Operations ManagerReveal Email/Phone
4
Social Media CoordinatorReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$84.8M42224%N/AN/A
#2
$0.4M20%N/AN/A
#3
$32M1593%N/AN/A
#4
$35M1213%$62.5MN/A
#5
$30.2M15018%N/AN/A
#6
$135.3M6730%N/AN/A
#7
$110.3M549N/AN/AN/A
#8
$60.1M299-4%N/AN/A
#9
$554.8M17252%N/AN/A
#10
$10.5M524%N/AN/A
Add Company

What Is Vivera Pharmaceuticals?

Vivera Pharmaceuticals, Inc. is an innovative, science-driven pharmaceutical company focused on opioid cessation and deterrence and non-addictive solutions for pain management. In addition to its pharmaceutical and medical device products, the Company has global exclusivity to license the patented and patent-pending TABMELT® sublingual drug-delivery system for select biopharmaceutical and pharmaceutical compounds. The Company is vertically integrated with patented technology, manufacturing capabilities and distribution for its products.

keywords:N/A

N/A

Total Funding

22

Number of Employees

$4.4M

Revenue (est)

-12%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Vivera Pharmaceuticals News

2022-04-17 - Vivera Enters $23 Billion Telehealth Industry with Patent ...

NEWPORT BEACH, Calif., April 21, 2022 /PRNewswire/ -- Vivera Pharmaceuticals, Inc. is pleased to announce that it has received a Notice of...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.5M220%N/A
#2
$2.7M2210%N/A
#3
$4.2M22-19%N/A
#4
$3.9M22-4%N/A
#5
$2.2M22N/AN/A